154 related articles for article (PubMed ID: 29749541)
1. Suppression of RRM2 inhibits cell proliferation, causes cell cycle arrest and promotes the apoptosis of human neuroblastoma cells and in human neuroblastoma RRM2 is suppressed following chemotherapy.
Li J; Pang J; Liu Y; Zhang J; Zhang C; Shen G; Song L
Oncol Rep; 2018 Jul; 40(1):355-360. PubMed ID: 29749541
[TBL] [Abstract][Full Text] [Related]
2. Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in ovarian cancer.
Zhang M; Wang J; Yao R; Wang L
Int J Gynecol Cancer; 2013 May; 23(4):659-66. PubMed ID: 23466567
[TBL] [Abstract][Full Text] [Related]
3. RRM2 promotes the progression of human glioblastoma.
Li C; Zheng J; Chen S; Huang B; Li G; Feng Z; Wang J; Xu S
J Cell Physiol; 2018 Oct; 233(10):6759-6767. PubMed ID: 29667764
[TBL] [Abstract][Full Text] [Related]
4. Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma.
Kang W; Tong JH; Chan AW; Zhao J; Wang S; Dong Y; Sin FM; Yeung S; Cheng AS; Yu J; To K
Oncol Rep; 2014 Jun; 31(6):2579-86. PubMed ID: 24756820
[TBL] [Abstract][Full Text] [Related]
5. Identification of osalmid metabolic profile and active metabolites with anti-tumor activity in human hepatocellular carcinoma cells.
Wu Z; Zhan Y; Wang L; Tong J; Zhang L; Lin M; Jin X; Jiang L; Lou Y; Qiu Y
Biomed Pharmacother; 2020 Oct; 130():110556. PubMed ID: 32763815
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting RRM2 to enhance the anticancer activity of chemotherapy.
Zhan Y; Jiang L; Jin X; Ying S; Wu Z; Wang L; Yu W; Tong J; Zhang L; Lou Y; Qiu Y
Biomed Pharmacother; 2021 Jan; 133():110996. PubMed ID: 33227712
[TBL] [Abstract][Full Text] [Related]
7. SiRNA-Mediated
Xue T; Wang L; Li Y; Song H; Chu H; Yang H; Guo A; Jiao J
Int J Med Sci; 2019; 16(11):1510-1516. PubMed ID: 31673243
[No Abstract] [Full Text] [Related]
8. Cancer Fighting SiRNA-RRM2 Loaded Nanorobots.
Sharma A; Kumar P; Ambasta RK
Pharm Nanotechnol; 2020; 8(2):79-90. PubMed ID: 32003677
[TBL] [Abstract][Full Text] [Related]
9. siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide.
Zuckerman JE; Hsueh T; Koya RC; Davis ME; Ribas A
J Invest Dermatol; 2011 Feb; 131(2):453-60. PubMed ID: 20944646
[TBL] [Abstract][Full Text] [Related]
10. Silencing RRM2 inhibits multiple myeloma by targeting the Wnt/β‑catenin signaling pathway.
Liu X; Peng J; Zhou Y; Xie B; Wang J
Mol Med Rep; 2019 Sep; 20(3):2159-2166. PubMed ID: 31322175
[TBL] [Abstract][Full Text] [Related]
11. Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo.
Heidel JD; Liu JY; Yen Y; Zhou B; Heale BS; Rossi JJ; Bartlett DW; Davis ME
Clin Cancer Res; 2007 Apr; 13(7):2207-15. PubMed ID: 17404105
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA.
Gao J; Chen H; Yu Y; Song J; Song H; Su X; Li W; Tong X; Qian W; Wang H; Dai J; Guo Y
Biomaterials; 2013 Dec; 34(38):10084-98. PubMed ID: 24060417
[TBL] [Abstract][Full Text] [Related]
13. Osalmid, a Novel Identified RRM2 Inhibitor, Enhances Radiosensitivity of Esophageal Cancer.
Tang Q; Wu L; Xu M; Yan D; Shao J; Yan S
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1368-1379. PubMed ID: 32763454
[TBL] [Abstract][Full Text] [Related]
14. Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair.
Lu AG; Feng H; Wang PX; Han DP; Chen XH; Zheng MH
World J Gastroenterol; 2012 Sep; 18(34):4704-13. PubMed ID: 23002339
[TBL] [Abstract][Full Text] [Related]
15. Ribonucleotide reductase subunit M2 is a potential prognostic marker and therapeutic target for soft tissue sarcoma.
Das B; Jain N; Mallick B
Gene; 2022 Jan; 808():145988. PubMed ID: 34624457
[TBL] [Abstract][Full Text] [Related]
16. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).
Mazzu YZ; Armenia J; Chakraborty G; Yoshikawa Y; Coggins SA; Nandakumar S; Gerke TA; Pomerantz MM; Qiu X; Zhao H; Atiq M; Khan N; Komura K; Lee GM; Fine SW; Bell C; O'Connor E; Long HW; Freedman ML; Kim B; Kantoff PW
Clin Cancer Res; 2019 Jul; 25(14):4480-4492. PubMed ID: 30996073
[TBL] [Abstract][Full Text] [Related]
17. An enhanced RRM2 siRNA delivery to rheumatoid arthritis fibroblast-like synoviocytes through a liposome‑protamine-DNA-siRNA complex with cell permeable peptides.
Wang X; Wang X; Sun J; Fu S
Int J Mol Med; 2018 Nov; 42(5):2393-2402. PubMed ID: 30106091
[TBL] [Abstract][Full Text] [Related]
18. RRM2 is a potential prognostic biomarker with functional significance in glioma.
Sun H; Yang B; Zhang H; Song J; Zhang Y; Xing J; Yang Z; Wei C; Xu T; Yu Z; Xu Z; Hou M; Ji M; Zhang Y
Int J Biol Sci; 2019; 15(3):533-543. PubMed ID: 30745840
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells.
Yang PM; Lin LS; Liu TP
Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31936661
[TBL] [Abstract][Full Text] [Related]
20. KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines.
Yoshida Y; Tsunoda T; Doi K; Tanaka Y; Fujimoto T; Machida T; Ota T; Koyanagi M; Takashima Y; Sasazuki T; Kuroki M; Iwasaki A; Shirasawa S
Anticancer Res; 2011 Jul; 31(7):2535-9. PubMed ID: 21873171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
